Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients

Vivian W.Y. Lee, Joyce H.S. You, Kenneth K.C. Lee, T. S. Chau, Mary M.Y. Waye, Gregory Cheng

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)


Background: Multiple factors can affect the anticoagulation effect of warfarin. The objective of this study was to determine the relationship between different clinical factors and outcomes of warfarin therapy in Hong Kong Chinese patients. Methods: The study was conducted at the anticoagulation clinic of the Prince of Wales Hospital from 1 April to 31 December 2003. Clinical data collected included demographics, indications of warfarin, dietary vitamin K consumption, and drug-drug interactions. Blood samples were obtained for the genetic polymorphism analysis of CYP 2C9. Linear and multiple regression analysis were used for statistical analysis to determine the correlation between variables and the importance of various factors as the determinants of warfarin dosage requirement. Results: A total of 63 patients were recruited. The mean warfarin dosage was 3.30 ± 2.23 mg/day. The warfarin dosage ranged from 0.75 to 12 mg/day. The mean age was 59 ± 14 years old. Age, dietary vitamin K consumption, chronic heart failure, atrial fibrillation, hypertension, smoking and drinking status were found to be factors statistically significant affecting warfarin dosage. We detected no single nucleotide polymorphism in CYP 2C9 exon 4. Conclusion: Age, dietary vitamin K consumption, warfarin indication for atrial fibrillation, co-morbid with CHF, smoking and drinking status were found to be the factors that affected the warfarin requirement in Hong Kong Chinese patients. However, the genetic polymorphism in exon 4 of CYP 2C9 may not be associated with the warfarin sensitivity in this patient population.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalJournal of Thrombosis and Thrombolysis
Issue number1
Publication statusPublished - Aug 2005
Externally publishedYes


  • Anticoagulation
  • CYP2C9
  • Genetic polymorphism
  • Warfarin

Cite this